GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients

Core Insights - GeneDx is expanding its rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs) through a collaboration with Epic, enhancing its commercial strategy and improving patient care [6][9] - The company has established one of the largest proprietary genomic datasets, with over 600,000 clinical exomes and genomes sequenced, enabling faster and more definitive clinical results [2][8] - GeneDx has experienced an 80% year-over-year increase in its rapid testing business, with Medicaid coverage now available in 11 states and growing commercial payor adoption [3][10] Company Developments - GeneDx is a key collaborator in the SeqFirst study at the University of Washington, which aims to improve access to routine rWGS for critically ill infants [7] - The integration with Epic's electronic health record (EHR) system will streamline access for health systems, enhancing the provider and patient experience [9] - The company is committed to ensuring access to genomic testing for all patients and is investing in understanding clinical utility in broader populations [10] Industry Impact - The use of rWGS in neonatal care is expected to improve clinical management and outcomes for critically ill infants by enabling early genetic condition diagnosis [4] - The GUARDIAN study is exploring the utility of genomic screening in healthy newborns, with initial data indicating a 2.6% true positive screening outcome rate [10] - GeneDx's focus on precision medicine is positioned to transform healthcare by leveraging its extensive genomic data and testing capabilities [8]